A previous study showed that tumor cells modified with a replication-deficient adenovirus expressing IL-24 can enhance the antitumor immune responses,30 while using nonlytic NDV as a vector to transfer IL-24 to tumor cells is superior to using replication-deficient adenovirus. The gene discussed is IL24; the disease is neoplasm.